Bio-Thera Solutions Announces Initiation of Phase I Clinical Trial for BAT1308, a Monoclonal Antibody Targeting PD-1
GUANGZHOU, China--(BUSINESS WIRE)--#PD1--Bio-Thera Solutions, Ltd. (SHA: 688177), a commercial-stage pharmaceutical company, today announced that dosing…